UK Medicines Information
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial
Information type:
Randomised controlled trials
Source:
The Lancet Diabetes & Endocrinology
Specialities:
Endocrine system disorders
Summary
In adults with acromegaly who were inadequately controlled on first-generation somatostatin analogue monotherapy (octreotide or lanreotide), both doses of pasireotide tested resulted in superior rates of biochemical control compared to continuation of octreotide/lanreotide.
UKMi comment
A Comment discussing this research is available at the link below.
Related links:
Comment